A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
March 6, 2026
LCZ696 (Sacubitril Valsartan )
4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate; Sacubitril Valsartan
CAS:936623-90-4
CF:C48H55N6O8Na3·2.5H2O
MW:957.99
Availability: R&D; Commercialization
LCZ696
⬤ CAS No. 936623-90-4
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | LCZ696 |
| Alternative Names | (S)-2-(N-((2′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)hexanamido)-3-methylbutanoic acid |
| CAS No. | 936623-90-4 |
| Molecular Formula | C48H55N6O8Na3·2.5H2O (Approximate, depending on salt form) |
| Molecular Weight | 957.99 (Approximate, including salts and hydrates) |
| Manufacturer | Shandong Tianming Pharmaceutical Group |
| Packaging | Multiple packaging options available, e.g., bottles |
| Storage | Typically at room temperature with protection from moisture and light |
| Solubility | Ethanol: 9 mg/mL, H2O: 92 mg/mL, DMSO: 45.45 mg/mL (Approximate, can vary) |
| Category | API |
| Note | Only supplied as an active pharmaceutical ingredient (API) or pharmaceutical intermediate for the development and production of subsequent drug preparations |
| Application | LCZ696 is a dual-acting angiotensin receptor neprilysin inhibitor with a unique mode of action |
Customer Reviews
Real customer feedback
Alexandra Thompson
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Ethan Lee
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Sophia Chen
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Lucas Rodriguez
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
What's News
Latest news at Tianming
CDMO vs. Direct Manufacturer: Which Model Fits Your API Strategy?
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
March 3, 2026
Case Study: Improving Yield & Purity Through Route Optimization
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).
February 27, 2026
Still Have Questions？
If you still have questions or need more information, our team is here to help. Please don’t hesitate to contact us for personalized assistance.